Tubulis Technologies

Executive Summary

Tubulis Technologies is a privately held, pre-clinical German biotech company headquartered in Munich, founded in 2019. The company is reimagining antibody-drug conjugates (ADCs) through its proprietary Alco5 conjugation platform, which recently demonstrated the ability to expand ADC payload scope in a publication in Nature Communications (January 2025). By enabling more stable and versatile conjugation, Tubulis aims to overcome key limitations of traditional ADCs, such as payload instability and off-target toxicity. The company's ADCs are designed to improve therapeutic index and broaden the applicability of ADCs in oncology and beyond.

Upcoming Catalysts (preview)

• Q3 2026Lead asset IND submission60% success
• Q4 2026Potential partnership or licensing deal for Alco5 platform50% success
• Q2 2026Series B or follow-on financing round70% success